FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1631769030> ?p ?o ?g. }

• W1631769030 abstract "Background Tiotropium is an anticholinergic agent which has gained widespread acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable chronic obstructive pulmonary disease (COPD). In the past few years there have been several systematic reviews of the efficacy of tiotropium, however, several new trials have compared tiotropium treatment with placebo, including those of a soft mist inhaler, making an update necessary. Objectives To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. Search methods We searched the Cochrane Airways Group's Specialised Register of Trials (CAGR) and ClinicalTrials.gov up to February 2012. Selection criteria We included parallel group RCTs of three months or longer comparing treatment with tiotropium against placebo for patients with COPD. Data collection and analysis Two review authors independently assessed studies for inclusion and then extracted data on study quality and the outcome results. We contacted study authors and trial sponsors for additional information, and collected information on adverse effects from all trials. We analysed the data using Cochrane Review Manager 5, RevMan 5.2. Main results This review included 22 studies of good methodological quality that had enrolled 23,309 participants with COPD. The studies used similar designs, however, the duration varied from three months to four years. In 19 of the studies, 18 mcg tiotropium once daily via the Handihaler dry powder inhaler was evaluated, and in three studies, 5 or 10 mcg tiotropium once daily via the Respimat soft mist inhaler was evaluated. Compared to placebo, tiotropium treatment significantly improved the mean quality of life (mean difference (MD) ‐2.89; 95% confidence interval (CI) ‐3.35 to ‐2.44), increased the number of participants with a clinically significant improvement (odds ratio (OR) 1.52; 95% CI 1.38 to 1.68), and reduced the number of participants with a clinically significant deterioration (OR 0.65; 95% CI 0.59 to 0.72) in quality of life (measured by the St George's Respiratory Questionnaire (SGRQ)). Tiotropium treatment significantly reduced the number of participants suffering from exacerbations (OR 0.78; 95% CI 0.70 to 0.87). This corresponds to a need to treat 16 patients (95% CI 10 to 36) with tiotropium for a year in order to avoid one additional patient suffering exacerbations, based on the average placebo event rate of 44% from one‐year studies. Tiotropium treatment led to fewer hospitalisations due to exacerbations (OR 0.85; 95% CI 0.72 to 1.00), but there was no statistically significant difference in all‐cause hospitalisations (OR 1.00; 95% CI 0.88 to 1.13) or non‐fatal serious adverse events (OR 1.03; 95% CI 0.97 to 1.10). Additionally, there was no statistically significant difference in all‐cause mortality between the tiotropium and placebo groups (Peto OR 0.98; 95% CI 0.86 to 1.11). However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: P = 0.01). With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92; 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%). It is noted that the rates of patients discontinuing study treatment were uneven, with significantly fewer participants withdrawing from tiotropium treatment than from placebo treatment (OR 0.66; 95% CI 0.59 to 0.73). Participants on tiotropium had improved lung function at the end of the study compared with those on placebo (trough forced expiratory volume in one second (FEV1) MD 118.92 mL; 95% CI 113.07 to 124.77). Authors' conclusions This review shows that tiotropium treatment was associated with a significant improvement in patients' quality of life and it reduced the risk of exacerbations, with a number needed to treat to benefit (NNTB) of 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalisation but no significant difference was found for hospitalisation of any cause or mortality. Thus, tiotropium appears to be a reasonable choice for the management of patients with stable COPD, as proposed in guidelines. The trials included in this review showed a difference in the risk of mortality when compared with placebo depending on the type of tiotropium delivery device used. However, these results have not been confirmed in a recent trial when 2.5 mcg or 5 mcg of tiotropium via Respimat was used in a direct comparison to the 18 mcg Handihaler." @default.
• W1631769030 created "2016-06-24" @default.
• W1631769030 creator A5004570305 @default.
• W1631769030 creator A5057607432 @default.
• W1631769030 creator A5083034782 @default.
• W1631769030 date "2014-07-21" @default.
• W1631769030 modified "2023-10-17" @default.
• W1631769030 title "Tiotropium versus placebo for chronic obstructive pulmonary disease" @default.
• W1631769030 cites W1483376681 @default.
• W1631769030 cites W1498865317 @default.
• W1631769030 cites W1534563031 @default.
• W1631769030 cites W1549988217 @default.
• W1631769030 cites W1575601674 @default.
• W1631769030 cites W1688903512 @default.
• W1631769030 cites W1704063072 @default.
• W1631769030 cites W1744311214 @default.
• W1631769030 cites W17572523 @default.
• W1631769030 cites W1928051214 @default.
• W1631769030 cites W1928394001 @default.
• W1631769030 cites W1950113648 @default.
• W1631769030 cites W1954671479 @default.
• W1631769030 cites W1970266583 @default.
• W1631769030 cites W1970893194 @default.
• W1631769030 cites W1971649226 @default.
• W1631769030 cites W1978457536 @default.
• W1631769030 cites W1981197711 @default.
• W1631769030 cites W1981720516 @default.
• W1631769030 cites W1985644458 @default.
• W1631769030 cites W1990744788 @default.
• W1631769030 cites W1999051703 @default.
• W1631769030 cites W2001361799 @default.
• W1631769030 cites W2005189963 @default.
• W1631769030 cites W2005640821 @default.
• W1631769030 cites W2011384746 @default.
• W1631769030 cites W2012835632 @default.
• W1631769030 cites W2017277255 @default.
• W1631769030 cites W2023869376 @default.
• W1631769030 cites W2029276834 @default.
• W1631769030 cites W2030732178 @default.
• W1631769030 cites W2032080378 @default.
• W1631769030 cites W2037965009 @default.
• W1631769030 cites W2043480884 @default.
• W1631769030 cites W2047130491 @default.
• W1631769030 cites W2048660493 @default.
• W1631769030 cites W2048919604 @default.
• W1631769030 cites W2056156074 @default.
• W1631769030 cites W2056267346 @default.
• W1631769030 cites W2060936551 @default.
• W1631769030 cites W2065601647 @default.
• W1631769030 cites W2066889593 @default.
• W1631769030 cites W2068959829 @default.
• W1631769030 cites W2070363722 @default.
• W1631769030 cites W2070935883 @default.
• W1631769030 cites W2072038990 @default.
• W1631769030 cites W2074087509 @default.
• W1631769030 cites W2081849910 @default.
• W1631769030 cites W2082198827 @default.
• W1631769030 cites W2094753948 @default.
• W1631769030 cites W2095052694 @default.
• W1631769030 cites W2096796935 @default.
• W1631769030 cites W2101932319 @default.
• W1631769030 cites W2102443712 @default.
• W1631769030 cites W2102825376 @default.
• W1631769030 cites W2106698492 @default.
• W1631769030 cites W2108738057 @default.
• W1631769030 cites W2109006492 @default.
• W1631769030 cites W2113026917 @default.
• W1631769030 cites W2114199224 @default.
• W1631769030 cites W2114656103 @default.
• W1631769030 cites W2116894543 @default.
• W1631769030 cites W2129929576 @default.
• W1631769030 cites W2130049277 @default.
• W1631769030 cites W2130181973 @default.
• W1631769030 cites W2132565543 @default.
• W1631769030 cites W2136626212 @default.
• W1631769030 cites W2140932829 @default.
• W1631769030 cites W2141034778 @default.
• W1631769030 cites W2142633372 @default.
• W1631769030 cites W2144711807 @default.
• W1631769030 cites W2149199480 @default.
• W1631769030 cites W2150866838 @default.
• W1631769030 cites W2153441442 @default.
• W1631769030 cites W2155409460 @default.
• W1631769030 cites W2157649793 @default.
• W1631769030 cites W2157823046 @default.
• W1631769030 cites W2160263482 @default.
• W1631769030 cites W2160426586 @default.
• W1631769030 cites W2165953097 @default.
• W1631769030 cites W2167941825 @default.
• W1631769030 cites W2313028042 @default.
• W1631769030 cites W2314896260 @default.
• W1631769030 cites W2320684523 @default.
• W1631769030 cites W2322501677 @default.
• W1631769030 cites W2324476328 @default.
• W1631769030 cites W2328043439 @default.
• W1631769030 cites W2328508257 @default.
• W1631769030 cites W2329012988 @default.
• W1631769030 cites W2329761638 @default.
• W1631769030 cites W2332561473 @default.
• W1631769030 cites W2335354385 @default.

• next